Skip to contentHome page Seeking Alpha - Power to InvestorsHong KongApr 18, 2026, 11:08 AM ETPrenetics Global Limited (PRE) StockStella Mwende2.12K FollowersCommentsPrenetics Global Limited (PRE) remains a buy, with a 15% near-term and 60% 24-month upside potential based on robust revenue growth projections.PRE’s strategic focus on IM8, divestiture of non-core assets, and global partnerships underpin its growth and profitability trajectory through 2027.Liquidity is strong with $100M cash and no debt, reducing dilution risk as PRE targets profitability by Q4 2027.AI-driven cost optimization and celebrity-backed marketing are expected to enhance margins and global brand reach, supporting PRE’s revenue and margin expansion goals.Elena Koroleva /iStock via Getty ImagesShares of consumer health brand, Prenetics Global Limited (PRE), have surged 12.35% since my last article on the company and are up 344.64% (YoY). Portfolio reorganization and capital reallocation contributed to the quarterlyThis article was written byStella Mwende2.12K FollowersI have more than five years experience in the financial industry. I focus mostly in the commodities, foreign exchange and cryptocurrencies. I also write on general issues like equity research, economics and geopolitics.Fellow contributor Crispus Nyaga is my colleague.Analyst’s Disclosure: I/we have a beneficial long position in the shares of PRE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.